Home › Calculator › VNDA Dividend Calculator 2026
VNDA Dividend DRIP Calculator 2026
37.52% YieldHealthcareVanda Pharmaceuticals Inc. · NASDAQ
Price: $5.33 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When VNDA pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your VNDA snowball 📈
$10,000 in VNDA → $5.90M in 10 years · $378,069.97/month
About Vanda Pharmaceuticals Inc. (VNDA) — Dividend Analysis 2026
Vanda Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic solutions that address critical unmet medical needs. The company currently offers two approved treatments: HETLIOZ, prescribed for non-24-hour sleep-wake disorders, and Fanapt oral tablets, used in the management of schizophrenia. Vanda maintains an active and diverse development pipeline, exploring new applications for its existing therapies and advancing a range of novel compounds. This includes expanding HETLIOZ (tasimelteon) to potentially treat conditions such as jet lag disorder, Smith-Magenis Syndrome, pediatric Non-24, autism spectrum disorder, and delayed sleep phase disorder. Fanapt (iloperidone) is being investigated for bipolar disorder, alongside the creation of a long-acting injectable formulation for schizophrenia. Other promising candidates in development include: Tradipitant (VLY-686): A small molecule neurokinin-1 receptor (NK-1R) antagonist for atopic dermatitis, gastroparesis, and motion sickness. VTR-297: A small molecule histone deacetylase inhibitor, primarily for hematologic malignancies but with broader oncology potential. VQW-765: A small molecule nicotinic acetylcholine receptor partial agonist targeting psychiatric disorders. A portfolio of cystic fibrosis transmembrane conductance regulator (CFTR) activators and inhibitors aimed at dry eye and ocular inflammation. BPO-27: For secretory diarrhea disorders, including cholera. VHX-896: The active metabolite of iloperidone. Vanda Pharmaceuticals Inc. markets its products in the United States, Europe, and Israel. The company was established in 2002 and is headquartered in Washington, D.C.
Compare VNDA with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full VNDA DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open VNDA position with:
🌍 VNDA Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold VNDA.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 37.52% | 34.72% | $3,752 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 31.89% | 29.09% | $3,189 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 30.02% | 27.22% | $3,002 / yr |
| 🇬🇧 UK ISA | 0% | 37.52% | 34.72% | $3,752 / yr |
| 🇬🇧 UK Taxable | 8.75% | 34.24% | 31.44% | $3,424 / yr |
| 🇨🇦 TFSA | 0% | 37.52% | 34.72% | $3,752 / yr |
| 🇨🇦 CA Taxable | 25% | 28.14% | 25.34% | $2,814 / yr |
| 🇦🇺 Super (pension) | 15% | 31.89% | 29.09% | $3,189 / yr |
| 🇦🇺 AU Taxable | 30% | 26.26% | 23.46% | $2,626 / yr |
| 🇩🇪 DE Taxable | 26.375% | 27.62% | 24.82% | $2,762 / yr |
| 🇫🇷 FR Taxable | 30% | 26.26% | 23.46% | $2,626 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 VNDA Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 VNDA Dividend Payment Schedule
VNDA pays quarterly — 4 times per year. Next ex-div: TBD.
📊 VNDA vs Healthcare Benchmarks
How VNDA compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for VNDA sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ VNDA Insider Activity
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| A-Award | 2026-06-04 | 80,000 | — | — | ||
| A-Award | 2026-06-04 | 41,600 | — | — | ||
| A-Award | 2026-06-04 | 41,600 | — | — | ||
| A-Award | 2026-06-04 | 41,600 | — | — | ||
| A-Award | 2026-06-04 | 41,600 | — | — | ||
| A-Award | 2026-06-04 | 41,600 | — | — | ||
| A-Award | 2026-06-04 | 41,600 | — | — | ||
| G-Gift | 2026-05-18 | 25,836 | — | — | ||
| A-Award | 2026-04-22 | 57,101 | — | — |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst Price Target
Wall Street consensusAnalyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the VNDA dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Vanda Pharmaceuticals Inc. (VNDA) is currently trading at $5.33, 75% below its 52-week high. The current dividend yield is 37.52% based on an annual payout of $2.00 per share.
VNDA (Vanda Pharmaceuticals Inc.) — 37.52% Dividend Yield Analysis
Vanda Pharmaceuticals Inc. (VNDA) is a healthcare stock currently trading at $5.33 with a dividend yield of 37.52%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
- Above-average yield (37.52%) may signal elevated risk — verify sustainability.
Auto-generated from live market data. For educational purposes only — not financial advice.
Latest VNDA News
LiveNews aggregated from public sources via Finnhub & RSS. For informational purposes only.